Bone is one of the most frequently transplanted tissues in the human body. Grafts of either autogenous or allogenic origin can be used to repair or replace missing or diseased parts of the skeleton. Autogenous bone is generally considered to be the best material for grafts, but it may give rise to morbidity at the donor site and it has limited availability. 1, 2 Allografts have been used successfully in a wide variety of clinical circumstances, but there are concerns regarding immunological reactions, the potential transmission of infectious diseases, and the loss of biological potential or biomechanical integrity as a result of various approaches to preservation or sterilisation. 3, 4 For these reasons, an alternative source of material for bone graft is appealing, especially if osteoinductive in nature.
The presence of osteogenic proteins in bone capable of inducing the formation of endochondral bone, was first described in 1965 by Urist. 5 Bone-inductive proteins, present in the matrix of demineralised bone, have been shown to cause the differentiation and proliferation of mesenchymal stem cells to osteogenic cells which are capable of participating in bony repair and osseous regeneration. [6] [7] [8] [9] [10] These bone-morphogenetic proteins (BMPs) are members of the supergene family of transforming growth factor-beta (TGF-ß). Many individual BMP molecules have been characterised and four are known to possess osteogenic activity. [11] [12] [13] [14] [15] In man, two BMP molecules have been particularly well described, BMP-7 (OP-1) and BMP-2, both of which have been isolated, sequenced, and manufactured using recombinant DNA techniques. The osteoinductive properties of recombinant human osteogenic protein (rhOP-1) have been well established in numerous animal models both in vitro and in vivo. These studies encouraged our investigation of OP-1, combined with a suitable carrier, as a potential facilitator of bone regeneration in man. [16] [17] [18] [19] [20] [21] Among various possible BMP carriers, 22 collagen type-I seemed suitable since it makes up more than 90% of the organic matrix of the bone. 23, 24 We designed a randomised, double-blind, prospective study to evaluate the effectiveness of rhOP-1 with a collagen type-I carrier to repair a critically-sized defect of fibular bone in man.
Patients and Methods
Design of the study. We studied 24 patients with a high tibial osteotomy for osteoarthritis of the knee who complied with the criteria of the study and had been followed up for one year. We used the bone gap at the site of the associated osteotomy of the fibula. The study consisted of two phases, each of which included two types of treatment. Six patients were assigned to one of the four groups. We first assessed whether the osteotomy would be suitable by comparing a group of patients in whom the gap had been left untreated with a second group in which demineralised bone (DMB) had been used to fill the defect. This showed that the site of the osteotomy would heal using standard techniques of bone grafting.
In the second phase we assessed the ability of OP-1 with a collagen type-I carrier, or of the latter alone, to repair the defect. This part of the randomised, prospective study was double-blinded.
Patients were assessed clinically, radiologically, and by dual-energy X-ray absorptiometry (DEXA) before operation and at 1, 6 and 10 weeks, 4 and 6 months and 1 year after. The possible presence of anti-OP-1 or anti-collagen type-I antibodies in the serum was also investigated.
The mean age at operation was 50 years (25 to 73) and the female-to-male ratio was 1:1.2. Operative procedure. The proximal tibial osteotomy was performed using an inverted 'V' technique and fixed with staples. 25 The fibular osteotomy was carried out at the junction of the middle and distal third of the bone, through a separate skin incision. 26 Depending on the extent of tibial correction, an osteoperiosteal fibular segment was removed. The resulting defect after correction measured approximately 15 mm, and was either left untreated or filled with one of the three graft materials (Fig. 1) . After operation, the leg was splinted with the knee in 10° of flexion. Postoperative management included six weeks in a plaster cast, beginning after one week. Protected weight-bearing was allowed after two weeks. Graft materials. We used three different graft materials: demineralised bone (DMB), OP-1 combined with a collagen type-I carrier (OP-1 device) and collagen type-I alone (collagen). The DMB consisted of 2.0 ml of demineralised particulate bone with glycerol resulting in an osseous gel (Grafton; BIS, Leiden, The Netherlands). The OP-1 device consisted of 2.5 mg of recombinant human osteogenic protein-1 and 1.0 g of purified insoluble bovine bone type-I collagen, reconstituted with 3.0 ml of 0.9% NaCl (Novos; Stryker Biotech, Natick, Massachusetts). The collagen alone was equivalent to the collagen type-I carrier of the OP-1 device and was also reconstituted with 3.0 ml of 0.9% NaCl (Stryker Biotech). Clinical evaluation. We determined the Hospital for Special Surgery (HSS) knee score, assessment of pain at the fibular osteotomy site and patient satisfaction.
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Radiological evaluation. Anteroposterior and lateral radiographs of the lower leg and ankle were taken at each review and evaluated blindly by two orthopaedic surgeons independently. The osseous response was classified as demonstrating either bone formation which bridged the distal and proximal parts of the fibular defect ('bridging'), bone formation not bridging the defect ('bone formation') or no bone formation ('no bone formation'). Differences between the two assessors were resolved by discussion with a third orthopaedic surgeon. DEXA evaluation. We determined changes in bone mineral density (BMD) within the fibular defect using DEXA. The bone mineral content (BMC) and area were used to derive the BMD (BMC in g/area in cm 2 ) for the area enclosed in a defined region of interest (ROI). The width of the ROI was standardised (24 mm) and the length was determined by the size of the fibular defect as recorded on the first postoperative scan. The positioning of the ROI was accomplished independently by two investigators who were blinded to the method of treatment. The preoperative value of the BMD within the ROI was defined retrospectively as baseline (100%) for postoperative comparisons. Scans were performed with a DPXL densitometer using SA Total Body Scan software (Lunar Corporation, Madison, Illinois) which is best suited to the soft-tissue conditions in the lower leg. OSTEOGENIC Immunological testing. To investigate immune responses to OP-1 or collagen, 5.0 ml of blood were obtained before operation and at follow-up at one and ten weeks from all patients in the double-blinded group treated with either the OP-1 device or collagen. The serum samples were analysed by the Chrysalis Company (Olyphant, Massachusetts). A minimum fourfold increase in antibody concentration (µg/ ml) after implantation of the collagen or OP-1 was classified as an antibody reaction. Statistical analysis. All the clinical report forms were reviewed by an independent monitor (Medpass International, Paris, France) before the data were processed. Descriptive statistics (range, mean, standard deviation, frequencies) were calculated of the clinical, radiological, DEXA and serum results at different periods of the followup.
The preoperative values (baseline) of BMD varied among the treatment groups. To prevent additional intergroup variability at further follow-up, one-way analysis of covariance (ANCOVA) was used to estimate differences in BMD between the treatment groups, adjusted for the preoperative variability in BMD between the patients. Before starting the statistical analysis, all BMD values were first transformed to logarithmic values to achieve more equality of variances. A p value of less than 0.05 was assumed to establish a significant difference. The data were analysed using SPSSWIN 7.5 PC-computer software (SPSS Benelux bv, Gorinchem, The Netherlands).
Results
The mean size of the fibular defects, as measured by DEXA, was 15.6 mm in the untreated group, 13.4 mm in the DMB group, 15.2 mm in the collagen group and 16.4 mm in the OP-1 group. Three patients each missed one follow-up appointment, one at one week after surgery and two at one year, although they were not known to be experiencing problems related to treatment. Clinical results. The HSS score increased in all groups over time and was comparable at each follow-up. The mean scores before operation and at one year after were 68 and 90, respectively. The severity of pain decreased overall from one week after operation and at one year there were no reports of pain except for three patients treated with OP-1 (Table I) . When questioned as to whether they were satisfied with the overall results of the surgery, 21 patients answered 'yes' and three 'no' at ten weeks and at one year; of those who were dissatisfied one was in the untreated group, one in the DMB group and one in the OP-1 group.
Two patients had complications in wound healing at the fibula during the perioperative period. One, treated with OP-1, had a haematoma on the lateral side of the lower leg at one week which resolved spontaneously by six weeks. The second, treated with collagen, had an oozing fibular wound for one week which required no intervention. Radiological results. Of the recorded radiological evaluations 20% had to be referred to the third orthopaedic surgeon; the results are presented in Table II . In the untreated and collagen group very little bone reaction was seen. All patients treated with DMB and five of the six treated with the OP-1 showed formation of new bone from six weeks onwards. Bridging was visible in four patients treated with the OP-1 and in one treated with DMB at this time. while that of patients treated with OP-1 started at the external borders (Figs 2 and 6) . DEXA findings. The mean values of BMD for the defect in each group at follow-up are shown in Table III . During the period of follow-up the mean BMD of the untreated and the collagen groups did not change significantly while that of the DMB and OP-1 groups increased by more than 80%. From four months onwards differences between both the untreated and DMB groups (p = 0.001) and the collagen and OP-1 device groups (p = 0.038) were statistically significant (Fig. 3) . There was no significant difference between the mean BMD of the untreated and the collagen groups and Radiographs showing a fibular defect after implantation with DMB at a) six and b) ten weeks and c) at one year. There was formation of new bone at six weeks, bridging at ten weeks and remodelling at one year. between the OP-1 and DMB groups at any time.
Study model validation.
For the purpose of validation of the model untreated defects were compared with the use of DMB. In the untreated group, few bony changes were observed. All patients treated with DMB showed new formation of bone by six weeks including one with bridging. Another three demonstrated bridging by ten weeks (Figs 2 and 4) .
OP-1 efficacy.
In the collagen group, minimal formation of bone was seen in three of the six patients at between six weeks and one year, with none bridging the defect completely (Fig 5) . All except one, treated with OP-1, showed new bone formation by six weeks, including four with bridging (Fig. 6) . By ten weeks, bridging was seen in a fifth patient. One patient in the OP-1 group showed no new bone formation at any point during the study. Radiographs showing an untreated fibular defect at a) six and b) ten weeks and c) at one year. There is no new formation of bone at any time. Radiographs showing a fibular defect after implantation with collagen type-I at a) six and b) ten weeks and c) at one year. There was no substantial formation of new bone or bridging at any time. Radiographs of a fibular defect after implantation with the OP-1 at six and ten weeks and at one year. There was substantial formation of bone with bridging at six weeks, more at ten weeks, increased by one year.
Immunological findings. Two patients treated with collagen alone developed an anti-collagen reaction by ten weeks after implantation (Table IV) . Clinically, however, no reactions were visible at the site of the fibular osteotomy nor were there any complaints. No patient developed detectable levels of antibodies to OP-1. Histological findings. One patient treated with OP-1 had persisting pain on the lateral side of the fibula with tingling near the lateral side of the ankle and pain in the joint. This patient had an exploration of the fibular gap 1.5 years after the tibial osteotomy. The defect, which appeared sound on radiographs, was seen to be bridged by a pseudarthrosis; the gap was resected. Histological examination of the removed bone fragment showed new bone formation (Fig. 7) .
Discussion
We have investigated the osteogenic activity of OP-1 in man by assessing its value in bridging a defect in the fibula made at the time of upper tibial osteotomy for valgus or varus deformity of the knee. In those in whom the defect was left untreated radiological and DEXA evaluation showed no formation of bone. When DMB was used the gap was bridged in four out of six patients within ten weeks. Statistical analysis showed a significant difference between the BMD in these two groups from four months onwards. The size of the gap at the site of the osteotomy is such that it will persist unless an osteogenic agent is introduced. It can therefore be used in man for assessing osteogenic activity. In the randomised, prospective, double-blind study comparing OP-1 combined with a type-I collagen carrier with collagen alone no bridging of bone was seen on the radiographs in the latter group. Collagen alone does not have the property to stimulate precursors of bone formation to induce adequate amounts of bone to bridge the defect. We suppose, as others have suggested, that due to the crosslinking of the collagen fibres, 28 Photomicrograph in polarised light of a bone fragment formed at a site implanted with OP-1 1.5 years before. Both lamellar and woven bone is seen ‫.)06ן(‬ formation of bone and bridging of the segmental defect occurred, with four of six fibular gaps bridged within six weeks. From four months onwards the differences between the BMD findings of the OP-1 group and the collagen type-I group alone were statistically significant. There were some characteristic similarities and differences between patients treated with DMB and OP-1. Both showed early formation of new bone which was first seen mainly along the medial side of the defect. This may be due to the proximity of the interosseous membrane between the fibula and the tibia, and its associated vascularity. Bridging was observed radiologically earlier with OP-1 than with DMB. The pattern differed between these groups. Patients treated with DMB showed a central formation within the medial and lateral borders of the defect, while those treated with OP-1 had a spherical formation which began at the external borders of the defect. Preferential stimulation by BMPs of periosteum-derived cells over bone-marrow derived cells may contribute to this different pattern. 29 The typical pattern of bone formed in the presence of OP-1 may also explain the remaining complaints of pain in three patients in the OP-1 group because of mechanical interference with muscle function. Bovine collagen, which was used as a carrier, has been used extensively in a variety of clinical circumstances. As in our study, collagen can act as a weak antigen, but these responses have not proved to be detrimental. The two patients who acquired a significant increase in serum values of collagen/antibody after implantation of the collagen, experienced no adverse events. We detected no significant increases in anti-OP-1 activity during the course of our study. One patient had a small and insignificant rise, less than twofold, in anti-OP-1 antibodies and was the only member of the OP-1 group who did not show any bone response. We do not have sufficient information, however, to establish a causal relationship between these two observations. Bone formed in the presence of OP-1 was retrieved in one patient in whom there were sufficient complaints of discomfort at the site of the fibular defect to justify local resection. Histological examination confirmed the presence of active bone remodelling. There was no evidence of residual collagen matrix when the specimen was recovered more than one year after implantation. It is presumed that the localised discomfort reflected an increased bulk of bone at the gap site which mechanically established irritation in adjacent soft tissues. These symptoms were relieved by excision of this bony response.
The bone which has been newly formed in the presence of the OP-1 combined with the results of in vitro and animal studies lead us to conclude that the concentrations of OP-1 needed in vitro may be higher than those for the stimulation of precursors in vivo. 20 The dose of human OP-1 given could therefore be too high, especially when dealing with normal bone. Currently, we do not know whether there is a difference in the dose of OP-1 required for healthy or diseased bone.
Our randomised, prospective, and double-blinded study has demonstrated the induction of bone by a recombinant human BMP molecule in a human clinical setting. No adverse reactions attributed to the OP-1 were observed. Further investigations are required to establish the efficacy of OP-1 in various musculoskeletal disorders to determine the dose-response profiles or effects of different carriers and to confirm the biological and biomechanical characteristics of regenerated new bone.
